| Identification | Back Directory | [Name]
B581 | [CAS]
149759-96-6 | [Synonyms]
B581
B581 USP/EP/BP
FTASE INHIBITOR I
H-Cys-()-Val-()-Phe-Met-OH
CYS-((R))-VAL-((R))-PHE-MET
H-CYS-(R)-VAL-(R)-PHE-MET-OH
H-Cys-psi(CH2NH)Val-psi(CH2NH)Phe-Met-OH
N-[(S)-2-((R)-2-Amino-3-mercapto-propylamino)-3-me
H-Cys-psi(CH2NH)Val-psi(CH2NH)Phe-Met-OH trifluoroacetate salt
N-[2(S)-[2(R)-AMINO-3-MERCAPTOPROPYLAMINO]-3-METHYL-BUTYL]-PHE-MET
N-[2(S)-[2(R)-AMINO-3-MERCAPTOPROPYLAMINO]-3-METHYLBUTYL]-PHE-MET-OH
N-[(S)-2-((R)-2-AMINO-3-MERCAPTO-PROPYLAMINO)-3-METHYL-BUTYL]-PHE-MET-OH
N-[(S)-2-((R)-2-AMino-3-Mercapto-propylaMino)-3-Methyl-butyl]-Phe-Met-OH, B581
N-[2(S)-(2(R)-2-AMINO-3-MERCAPTOPROPYLAMINO)-3-METHYLBUTYL]-L-PHENYLALANYL-L-METHIONINE
L-Methionine, N-[(2S)-2-[[(2R)-2-amino-3-mercaptopropyl]amino]-3-methylbutyl]-L-phenylalanyl-
N-[2(S)-(2(R)-2-Amino-3-mercaptopropylamino)-3-methylbutyl]-L-phenylalanyl-L-methionine trifluoroacetate salt
(2S)-2-({(2S)-2-[((2S)-2-{[(2R)-2-aMino-3-sulfanylpropyl]aMino}-3-Methylbutyl)aMino]-3-phenylpropanoyl}aMino)-4-(Methylsulfanyl)butanoic acid | [Molecular Formula]
C22H38N4O3S2 | [MDL Number]
MFCD00236999 | [MOL File]
149759-96-6.mol | [Molecular Weight]
470.69 |
| Chemical Properties | Back Directory | [Boiling point ]
716.1±60.0 °C(Predicted) | [density ]
1.161±0.06 g/cm3(Predicted) | [storage temp. ]
−20°C | [solubility ]
H2O: soluble | [form ]
solid | [pka]
3.04±0.10(Predicted) | [color ]
white | [Water Solubility ]
water: 1mg/mL
DMSO: 5mg/mL |
| Hazard Information | Back Directory | [Description]
FTase inhibitor I is a potent inhibitor of farnesyltransferase (FTase; IC50 = 21 nM) that is greater than 30-fold selective for FTase over geranylgeranyl transferase (GGTase; IC50 = 790 nM). It prevents farnesylation of Ras and inhibits proliferation of cells transformed by Ras farnesylation. In a dog model of subarachnoid hemorrhage, it reduces GTP-Ras in spastic basilar arteries, decreases angiographic vasospasm, and improves clinical scores. | [Uses]
FTase Inhibitor I is a potent, selective, peptidomimetic FTase inhibitor. | [Definition]
ChEBI: A dipeptide obtained from the tetrapeptide Cys-Val-Phe-Met by reduction of the amide carbonyl groups of the Cys and Val residues. | [Enzyme inhibitor]
This cell-permeable CAAX peptidomimetic (FW = 470.70 g/mol; FWtrifluoracetate-salt = 583.71 g/mol; CAS 149759-96-6), named as N-[2(S)- (2(R)-2-amino-3-mercaptopropylamino)-3-methylbutyl]-L-phenylalanyl-L methionine), binds to and prevents protein farnesyltransferase (IC50 = 21 nM) from interacting with C-terminal L-Cys-L-Val-L-Phe-L-Met substrate recognition sequences that are present in its natural substrates. Otherwise hydrophilic proteins associate with membranes by means of enzymatic attachment of hydrophobic moieties to their C-termini. Whereas prenylation occurs in the cytosol, post-prenylation processing is accomplished on the cytoplasmic surface of the endoplasmic reticulum and Golgi apparatus. B581 inhibits prenylation and processing of H-ras and lamin A. B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
Alabiotech Inc.
|
| Tel: |
001-619-354-5251 |
| Website: |
www.alabiotech-e.com |
|